Abstract:Introduction: Eravacycline (ERV), a novel tetracycline derivative, exhibits broad-spectrum antibacterial activity, but data on the bacterial activity against Chinese bacterial isolates are very scarce. This study aims to evaluate the activity of eravacycline against the common Gram-positive and Gram-negative bacteria isolates in Guangdong, China. Methods: The clinical isolates were collected from four centers between 1 November 2023 and 31 January 2024, and the susceptibility of eravacycline (MIC 50 , MIC 90 , and MIC) was determined using broth microdilution as a reference method and E-TEST strips to evaluate their consistency. A total of 594 strains were collected from the four centers, including Staphylococcus aureus ( n = 126), Enterococcus faecalis ( n = 58), Enterococcus faecium ( n = 29), Klebsiella pneumoniae ( n = 136), Escherichia coli ( n = 187), and Acinetobacter baumannii ( n = 58). Results and discussion: The MIC 50 and MIC 90 (mg/L) of eravacycline were 0.12 and 1 for S. aureus, 0.06 and 0.12 for E. faecalis , 0.06 and 0.5 for E. faecium , 0.25 and 0.5 for E. coli , 0.5 and 2 for K. pneumoniae , and 0.25 and 2 for A. baumannii . Based on the FDA and EUCAST breakpoints, the susceptibility of eravacycline against S. aureus was 46.03% vs. 83.33%, 56.90% vs. 94.93% against E. faecalis , and 62.07% vs. 79.31% in E. faecium . The susceptibility rates of E. coli and K. pneumoniae were 90.37% and 58.09, respectively. To evaluate the performance between the broth microdilution test (BMD) and ETEST methods, we compared essential agreement (EA), categorical agreement (CA), very major error (VME), and major error (ME). The results demonstrated that compared with BMD, eravacycline measured by ETEST had higher VME and ME referring to FDA breakpoints than EUCAST breakpoints in the Gram-positive isolates. Since there were no intermediate breakpoints for the eravacycline, the MIC values measured by the ETEST method might result in lower CA and higher VME and ME. This study provides MIC values of eravacycline against Gram-positive and Gram-negative pathogens in four hospitals in Guangdong Province, and eravacycline is an effective therapeutic candidate for common bacteria.

In vitro antibacterial activity of doripenem

Study of in vitro bactericidal activity and resistance mutant of doripenem

Investigation of antibacteriocidal activity of domestic meropenem on β-lacta-mases-producing gram negativ bacilli in vitro

In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China

Study on the antibacterial activity of three carbapenems to the strains isolated from ICU

In Vivo Activity of Doripenem in the Experimental Model of Mouse Septicemia Infected by Bacteria

In Vitro Efficacy of Doripenem against Pseudomonas aeruginosa and Acinetobacter baumannii by E-Test

Effect of Doripenem on Pseudomonas aeruginosa Biofilm Formation and the Quorum Sensing System

Comparison of Antibacterial Activity in Vitro of Two Pharmaceutical Products of Meropenem Injection

In vitro antibacterial activity of three agents of carbapenems

Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations.

In vitro activities of tebipenem pivoxil against clinical isolates

In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China

In vitro activity of antimicrobial agents against Enterococcus spp

Red Bayberry Extract Inhibits Growth and Virulence Gene Expression of the Human Pathogen Vibrio Cholerae.

In vitro activities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China

[A study of in vitro activity of daptomycin against 2679 Gram-positive cocci].

Evaluation of Phenotypic Tests for Detection of Metallo-β-Lactamase-Producing Pseudomonas Aeruginosa Strains in China

In vitro activities of 16 antimicrobial agents against Gram-negative bacteria from six teaching hospitals in China.

In Vitro Activity of Imipenem/Relebactam Against Enterobacteriaceae Isolates Obtained from Intra-abdominal, Respiratory Tract, and Urinary Tract Infections in China: Study for Monitoring Antimicrobial Resistance Trends (SMART), 2015–2018

In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa